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ABSTRACT 
The purpose of this research was to develop a novel gastroretentive drug delivery system based on wet granulation technique for 
sustained delivery of active agent. Quick GI transit could result in incomplete drug release from the drug delivery system above the 
absorption zone leading to decreased efficacy of the administered dose and thus less patient compliance. Gastroretentive floating 
tablets, which was designed to provide the desired sustained and complete release of drug for prolonged period of time. 
Gastroretentive floating tablets of lafutidine were prepared by wet granulation technique using different concentrations of Gum 
Kondagagu, Gum olibanum and Locust bean Gum. The optimized formulation (LF14) exhibited 99.54% drug release in 12 hrs, 
while the buoyancy lag time was 33 sec. In-vitro drug release kinetics was found to follow both the Zero order and the possible 
mechanism of lafutidine release from the optimized formulation might be attributed to super case II transport mechanism. The 
Optimized formulation (LF14) showed no significant change in physical appearance, drug content, floating lag time, in vitro 
dissolution studies after 75%±5% RH at 40±20C relative humidity for 6 months. 
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INTRODUCTION 
Oral administration is the most versatile, convenient and 
commonly employed route of drug delivery for systemic 
action .Oral controlled release drug delivery have 
recently been of increasing interest in pharmaceutical 
field to achieve improved therapeutic advantages, such 
as ease of dosing administration, patient compliance and 
flexibility in formulation. A controlled drug delivery 
system with prolonged residence time in the stomach is 
of particular interest for drugs that are locally active in 
the stomach, have narrow absorption window in 
gastrointestinal tract, are primarily absorbed from 
stomach and upper part of GIT, are unstable in the 
intestinal or colonic environment, disturb normal colonic 
bacteria and exhibit low solubility at high pH values. 
Gastro retentive dosage form can remain in the gastric 
region for several hours and hence significantly prolong 
the gastric residence time of drugs. Prolonged gastric 
retention improves bioavailability, reduces drug waste, 
and improves solubility of drugs that are less soluble in a 
high pH environment. Gastro retention helps to provide 
better availability of new products with suitable 
therapeutic activity and substantial benefits for patients 
1,2
.  
Lafutidine has newly developed 2
nd
 generation H2 
antihistaminic blocker. It is exceedingly helpful in 
gastric and duodenal ulcers. It prevents the gastric 
mucosal lesions in both acute and chronic gastritis. The 
lafutidine penetrates the stomach wall and binds the H2 
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receptors. The lafutidine also increases the blood flow to 
gastric mucosa. It shows protective action in an 
experimental model 
3.
 
MATERIALS AND METHODS 
Materials: 
The Lafutidine was obtained as a gift sample from 
splendid laboratories, Pune. Gum Kondagogu, Gum 
Olibanum and Locust Bean Gum were obtained from 
Girijan Co-operative corp. Ltd, Hyderabad.  Sodium 
bicarbonate, Citric acid, PVP-K30 was gifted from MSN 
Labs Ltd, Hyderabad. All other chemicals used were of 
analytical grade. 
 
Methods: 
Wet Granulation Method 
4
 
Gastroretentive floating tablets of lafutidine were 
prepared by wet granulation technique using different 
concentrations of Gum Kondagagu, Gum olibanum and 
Locust bean Gum. All the ingredients were passed 
through sieve no 85# and were mixed uniformly. 
Granulation was carried out with sufficient quantity of 
binder solution (PVP K 30 - 5% in isopropyl alcohol). 
The wet mass was passed through sieve no 12# and 
dried at 45
0
C for 2 hr. Dried granules were sized by 
sieve no.18# add magnesium stearate and talc. Granules 
obtained were compressed with 8 mm flat punch 
(Cadmach, Ahmedabad, India). 
  
Table 1: Formulation trials of floating tablets of Lafutidine using Locust bean gum 
Ingredients LF1 LF2 LF3 LF4 LF5 LF6 LF7 LF8 
Drug 10 10 10 10 10 10 10 10 
Locust bean 
 gum 
30 40 50 60 30 40 50 60 
    Sodium 
Bicarbonate 
30 30 30 30 45 45 45 45 
Citric acid 10 10 10 10 10 10 10 10 
MCC 150 140 130 120 135 125 115 105 
PVP K-30 10 10 10 10 10 10 10 10 
Mg stearate 5 5 5 5 5 5 5 5 
Talc 5 5 5 5 5 5 5 5 
Total weight 250 250 250 250 250 250 250 250 
 
Table 2: Formulation trials of floating tablets of Lafutidine using Gum Kondagogu 
Ingredients LF9 LF10 LF11 LF12 LF13 LF14 LF15 LF16 
Drug 10 10 10 10 10 10 10 10 
Gum Kondagogu 50 70 90 110 50 70 90 110 
Sodium Bicarbonate 30 30 30 30 45 45 45 45 
Citric acid 10 10 10 10 10 10 10 10 
MCC 130 110 90 70 115 95 75 55 
PVP K-30 10 10 10 10 10 10 10 10 
Mg stearate 5 5 5 5 5 5 5 5 
Talc 5 5 5 5 5 5 5 5 
Total weight 250 250 250 250 250 250 250 250 
 
Table 3: Formulation trials of floating tablets of Lafutidine using Locust bean gum  
Ingredients LF17 LF18 LF19 LF20 LF21 LF22 LF23 LF24 
Drug 10 10 10 10 10 10 10 10 
Gum Olibanum 65 75 85 95 65 75 85 95 
Sodium Bicarbonate 30 30 30 30 45 45 45 45 
Citric acid 10 10 10 10 10 10 10 10 
MCC 105 95 85 75 80 70 60 50 
PVP K-30 10 10 10 10 10 10 10 10 
Mg stearate 5 5 5 5 5 5 5 5 
Talc 5 5 5 5 5 5 5 5 
Total weight 250 250 250 250 250 250 250 250 
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Evaluation Parameters 
Precompression parameters 
5,6
 
Prior to the compression, the formulation powder blends 
were evaluated for their bulk and tapped density and 
from these values compressibility index and Hausner’s 
ratio were calculated. While the flow properties of the 
powder bled were accessed from the angle of repose 
4
. 
Evaluation of Floating Tablets 
7,8 
Post compression parameters: The prepared tablets 
were evaluated for quality control tests like weight 
variation, hardness, thickness, friability and content 
uniformity. 
Weight variation: Ten tablets were selected randomly 
from each batch and weighed individually, calculating 
the average weight and comparing the individual tablet 
weight to the average. From this; percentage weight 
difference was calculated and then checked for USP 
specifications. 
Hardness and friability: Hardness of tablet was 
determined by Monsanto hardness Tester. Ten tablets 
were randomly picked from each batch and analyzed for 
hardness. The mean and standard deviation were also 
calculated. Friability test was done by Roche friabilator. 
Ten tablets were weighed and were subjected to the 
combined effect of attrition and shock by utilizing a 
plastic chamber that revolve at 25 rpm dropping the 
tablets at distance of 6 in. with each revolution. 
Operated for 100 revolutions, the tablets were de-dusted 
and reweighed. The percentage friability was calculated. 
In vitro buoyancy studies: The in vitro buoyancy was 
determined floating lag time, as per the method 
described by Rosa et al. The tablets were placed in a 250 
ml beaker, containing 200 ml of 0.1 N HCl. The time 
required for the tablet to rise to the surface and float was 
determined as Floating Lag Time (FLT) and the time 
period up which the tablet remained buoyant is 
determined as Total Floating Time (TFT). 
In vitro Dissolution Studies: The In vitro dissolution 
study was performed by using a United States 
Pharmacopeia (USP) type II (paddle) apparatus at a 
rotational speed of 100 rpm. Exactly 900 ml of 0.1 N 
HCl was used as the dissolution medium and the 
temperature was maintained at 37
o
C ± 0.5
o
C. A sample 
(10 ml) of the solution was withdrawn from the 
dissolution apparatus at specified time interval for 12 
hrs and the same volume was replaced with pre -warmed 
fresh dissolution media. The samples were filtered 
through a whattman filter paper and diluted to a suitable 
concentration with 0.1 N HCl. Absorbance of these 
solutions was measured at 220 nm using a UV 
spectrophotometer. 
Stability studies: The optimized formulation of 
lafutidine were packed in strips of 0.04 mm thick 
aluminum foil laminated with poly vinyl chloride by 
strip packing and these packed formulations were stored 
in ICH certified stability chambers (Thermo labs, 
Mumbai) maintained at 40 
0
C and 75% RH for  6 
months. The samples were withdrawn periodically and 
evaluated for their floating lag time, content uniformity 
and for in vitro drug release 
9
. 
RESULTS AND DISCUSSION 
In the present work, lafutidine used in the treatment of 
ulcer has been utilized as an active drug and considered 
to be good candidate for reducing dose frequency, for 
solid oral sustained release formulation as well as more 
compliance in ulcers. The present it in the form of 
gastroretentive floating tablets to provide the desired 
sustained and complete release for prolonged period of 
time. 
Precompression Parameters 
The results of precompression evaluation parameters are 
shown in (Table 4). All the precomression evaluation 
parameters were within the USP Pharmacopoeia limits. 
Postcompression Parameters 
The results of postcompression evaluation parameters 
are shown in (Table 5). The Weight variation of all 
formulations witnessed to be in the limit allowed that is 
± 5% of total tablet weight. The suitable hardness for 
compressed tablets is considered as a vital function for 
the end user. The deliberated crushing strength of 
fabricated tablets of formulations F1-F24 trended 
between 4.0-5.0kg/cm
2
. The thickness of all the 
formulations ranges from 4.1-4.5 mm. The friability of 
all prepared formulation between 0.53-0.79 percent, the 
friability properties limits are in between 0-1%. The 
drug content of all formulation is in between 94.23-
99.68%, drug content depends on the angle of repose 
since the angle of repose indicates uniform flow nature 
of powder blend which makes the drug to evenly 
distribute in all the formulation and to maintain content 
uniformity in all batches.  Tablets of all batches had 
floating lag time below 60 seconds regardless of 
viscosity and content of polymers because of evolution 
of CO2 resulting from the interaction between sodium 
bicarbonate and dissolution medium, entrapment of gas 
inside the hydrated polymeric matrices enables the 
dosage form to float by lowering the density of the 
matrices. Total Floating time for the natural polymers 
formulations were more than 12 hrs. 
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Table 4: Physical properties of prepared powder blends of Floating tablet 
Formulation 
 
Bulk density 
(g/cc) 
Tapped density 
(g/cc) 
Angle of 
repose(ϴ) 
  rr  s    e  
(%) 
H us er’s ratio 
LF1 0.56±0.02 0.54±0.01 24.34±0.4 10.23±0.8 1.13±0.02 
LF2 0.58±0.12 0.58±0.04 23.67±0.3 10.23±1.0 1.11±0.07 
LF3 0.59±0.04 0.64±0.05 26.54±0.1 10.12±0.7 1.13±0.09 
LF4 0.50±0.04 0.68±0.04 23.89±0.2 11.34±0.6 1.14±0.03 
LF5 0.65±0.02 0.59±0.02 22.56±0.1 11.23±0.8 1.11±0.05 
LF6 0.50±0.21 0.66±0.12 23.30±0.1 10.23±0.5 1.12±0.06 
LF7 0.52±0.06 0.64±0.03 25.56±0.2 10.34±1.0 1.14±0.06 
LF8 0.53±0.01 0.68±0.03 24.67±0.3 10.11±0.8 1.12±0.03 
LF9 0.57±0.01 0.61±0.01 25.56±0.3 10.45±0.7 1.13±0.02 
LF10 0.58±0.13 0.67±0.06 22.66±0.2 11.45±0.5 1.15±0.01 
LF11 0.53±0.09 0.68±0.12 25.34±0.2 10.23±0.5 1.13±0.01 
LF12 0.57±0.06 0.64±0.21 22.99±0.5 11.34±0.5 1.12±0.01 
LF13 0.54±0.01 0.67±0.04 25.14±0.3 10.67±0.4 1.11±0.02 
LF14 0.51±0.04 0.66±0.07 21.09±0.2 09.23±0.4 1.10±0.03 
LF15 0.53±0.01 0.63±0.04 22.78±0.4 10.45±0.3 1.10±0.02 
LF16 0.54±0.02 0.61±0.07 22.45±0.4 10.68±0.2 1.13±0.02 
LF17 0.59±0.21 0.68±0.03 25.09±0.3 11.47±0.8 1.12±0.02 
LF18 0.58±0.03 0.67±0.08 23.05±0.2 11.99±0.3 1.14±0.02 
LF19 0.56±0.02 0.61±0.12 25.06±0.2 11.45±0.6 1.13±0.01 
LF20 0.59±0.06 0.64±0.1 24.78±0.1 10.12±0.5 1.15±0.01 
LF21 0.59±0.07 0.63±0.03 25.34±0.4 11.09±0.4 1.16±0.02 
LF22 0.56±0.15 0.63±0.04 24.12±0.3 10.34±0.2 1.14±0.03 
LF23 0.58±0.13 0.66±0.13 24.45±0.3 10.67±0.4 1.14±0.02 
LF24 0.56±0.12 0.68±0.05 25.56±0.2 09.68±0.6 1.14±0.05 
 
Table 5: Physicochemical parameters of lafutidine floating tablets 
F. No 
 
*Weight 
variation 
(mg) 
#Thickness 
(mm) 
#Hardness 
(Kg/Cm
2
) 
#Friability 
(%) 
#Content 
uniformity 
(%) 
Floating lag 
time 
(sec) 
Total 
floating 
time (hrs) 
F1 249.65±1.2 4.4±0.12 4.3±0.12 0.57±0.01 95.23±0.63 55 >12 
F2 251.69±0.8 4.3±0.06 4.1±0.06 0.55±0.02 97.04±0.06 52 >12 
F3 248.04±0.5 4.3±0.06 4.1±0.06 0.63±0.03 95.56±0.14 50 >12 
F4 250.05±0.0 4.2±0.12 5.2±0.12 0.72±0.01 98.11±1.01 47 >12 
F5 251.54±0.4 4.3±0.00 4.3±0.00 0.62±0.02 94.23±1.08 44 >12 
F6 250.78±0.4 4.3±0.10 5.1±0.06 0.66±0.01 95.45±0.31 42 >12 
F7 252.65±0.3 4.1±0.10 4.3±0.10 0.53±0.02 98.91±0.49 40 >12 
F8 249.57±0.2 4.3±0.25 5.3±0.40 0.69±0.01 97.23±0.51 57 >12 
F9 250.76±0.3 4.3±0.06 5.3±0.06 0.58±0.00 96.13±0.56 55 >12 
F10 248.49±0.2 4.2±0.20 4.2±0.42 0.79±0.02 95.23±0.24 52 >12 
F11 251.53±0.4 4.2±0.06 5.3±0.06 0.76±0.01 97.97±0.21 49 >12 
F12 250.58±0.3 4.2±0.00 4.4±0.06 0.73±0.02 98.45±0.76 46 >12 
F13 251.34±0.2 4.3±0.26 4.8±0.35 0.72±0.02 97.45±0.48 43 >12 
F14 250.67±0.3 4.1±0.21 5.4±0.21 0.54±0.03 99.68±0.23 33 >12 
F15 249.65±0.2 4.4±0.06 5.0±0.23 0.65±0.02 96.45±0.36 58 >12 
F16 250.65±0.3 4.2±0.25 4.4±0.23 0.68±0.01 96.45±0.69 55 >12 
F17 251.79±0.4 4.5±0.15 5.8±0.32 0.59±0.01 96.34±0.35 53 >12 
F18 251.87±0.1 4.4±0.25 4.7±0.35 0.68±0.01 97.56±0.23 50 >12 
F19 249.65±0.2 4.4±0.06 4.0±0.23 0.75±0.02 96.45±0.36 47 >12 
F20 249.32±0.2 4.2±0.12 5.5±0.20 0.63±0.03 97.18±0.81 45 >12 
F21 250.16±0.8 4.0±0.10 4.2±0.81 0.52±0.89 95.23±0.13 51 >12 
F22 251.33±0.2 4.3±0.15 5.3±0.25 0.61±0.23 97.59±0.65 48 >12 
F23 249.58±0.7 4.1±0.33 4.8±0.12 0.58±0.55 96.38±0.33 54 >12 
F24 250.11±0.4 4.5±0.28 4.5±0.45 0.71±0.67 98.42±0.27 49 >12 
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Figure 1: Comparison of in vitro Percentage drug release of lafutidine floating tablet formulations LF1-LF8 
 
Figure 2: Comparison of in vitro Percentage drug release of lafutidine floating tablet formulations LF9-LF16 
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Figure 3: Comparison of in vitro Percentage drug release of lafutidine floating tablet formulations LF17-LF24 
From the above figures (Figure 1, 2 and 3) it can be 
observed that the polymer Gum Kondagogu has 
sustaining effect on the release of drug from the floating 
matrix tablet of lafutidine compared to Locust bean gum 
and Gum olibanum. The difference in the drug release 
profiles of various formulations was due to the presence 
of different concentrations of natural polymers. The 
concentration of polymer was added in increasing order 
to check its drug release retarding ability and LF14 was 
considered as best formulation among the all the 
formulations. LF14 showed good buoyancy properties 
and sustained the drug release for desired period of time 
(12hrs). The release profiles from all these formulations 
followed diffusion controlled release, complying with 
higher correlation coefficient values of Higuchi and 
Peppas equations.  
Mathematical treatment of optimized formula of 
lafutidine floating tablets 
In vitro dissolution has been identified as a vital part of 
drug development. It could be used for assessment of 
bioequivalence. There are several models to represents 
the drug dissolution profiles where it is a function of 
time associated with the amount of drug dissolved in 
distinction to the dosage form. The quantitative 
interpretation of the values collected in the dissolution 
assay is facilitated by the usage of a generic equation 
that mathematically interprets the dissolution curve in 
the function of some parameters related to the 
formulations. 
A water soluble drug assimilated in a matrix is mainly 
liberated by diffusion, while for a low water- soluble 
drug the self-erosion of the matrix will be the principal 
release mechanism. Mathematical modeling of the 
release kinetics of specific classes of controlled-release 
systems may be used to predict solute release rates from 
and solute diffusion behavior through polymers and 
elucidate the physical mechanisms of solute transport by 
simply comparing the release data to mathematical 
models. 
In the view of the establishment of the release 
mechanism and quantitatively interpreting and translate 
mathematically the dissolution date being plotted. 
CONCLUSION 
In the present work, it can be concluded that the 
lafutidine floating tablets can be an innovative and 
promising approach for the delivery of lafutidine for the 
treatment of gastric ulcers. The optimized formulation 
LF14 containing Gum Kondagagu and a gas-generating 
agent. In-vitro release profile of lafutidine and marketed 
product when compared, the optimized formulation 
LF14 showed drug release of 99.54±1.26 % within 12h 
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whereas 99.54 % of the drug was released from the 
marketed product within 12h. The major mechanism of 
drug release follows zero order kinetics and non fickian 
transport by coupled diffusion and erosion. This means 
that water diffusion and also the polymer rearrangement 
have an essential role in the drug release. The release 
rate constant of optimized formulation LF14 was low 
enough prolonging drug delivery. This result is 
encouraging, because a longer gastric residence time is 
an important condition for higher bioavailability of the 
drugs included in the prolonged or sustained release 
dosage forms. 
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